GlassScriptPhysician profile
Alicia Lynn Morris
NPI 1043797228
$4,492.45
in general payments reported to CMS, 2019-2025
30 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,098 · 2022: $1,097 · 2023: $878 · 2024: $587 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $676.87 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $445.12 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.11 | 2021-2023 | Jardiance |
| Abbvie INC. | $373.76 | 2021-2025 | |
| Novo Nordisk INC | $356.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $332.18 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $247.92 | 2021-2023 | |
| Astellas Pharma US INC | $243.55 | 2021-2024 | Veozah |
| Amgen INC. | $239.42 | 2022-2025 | Evenity, Repatha, Otezla |
| Radius Health, INC. | $211.73 | 2023-2025 | Tymlos |
| Biohaven Pharmaceutical Holding Company LTD. | $184.24 | 2022 | |
| Pfizer INC. | $123.43 | 2021-2022 | |
| Esperion Therapeutics, INC. | $117.91 | 2021-2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $79.75 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $64.63 | 2022-2023 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $50.39 | 2024-2025 | Interstim |
| Biohaven Pharmaceuticals, INC. | $46.46 | 2021 | |
| Abbott Laboratories | $39.75 | 2023 | Freestyle Libre 3 |
| Eisai INC. | $36.89 | 2021-2024 | |
| Cardiovascular Systems INC. | $34.56 | 2023 | |
| Supernus Pharmaceuticals, INC. | $34.48 | 2023-2024 | Qelbree, Qelbree, Tlando |
| Takeda Pharmaceuticals U.S.A., INC. | $32.05 | 2023-2024 | Trintellix |
| Dexcom, INC. | $27.59 | 2021-2023 | Dexcom G6 Transmitter |
| Corium, LLC | $26.55 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $18.03 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $15.07 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $14.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.49 | 2023 | |
| Halozyme INC | $12.83 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.